We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Changing Treatment Paradigms for Brain Metastases From Melanoma: PART 2: When and How to Use the New Systemic Agents.
- Authors
Venur, Vyshak Alva; Funchain, Pauline; Kotecha, Rupesh; Chao, Samuel T.; Ahluwalia, Manmeet S.
- Abstract
Until recently, therapeutic strategies for melanoma brain metastases focused on local treatments: surgery, whole-brain radiation therapy, and stereotactic radiosurgery. Historically, systemic therapy had limited utility. Immunotherapeutic drugs, such as anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed death 1 agents, and agents targeting the BRAF-MEK pathway have revolutionized the systemic treatment of melanoma brain metastases. Recent clinical trials of these agents have shown activity against melanoma brain metastases, and they are increasingly being used in clinical practice. In this article, we provide an overview of the currently available systemic agents, including immunotherapeutic agents and targeted tyrosine kinase inhibitors. We also provide a practical management algorithm to guide the practicing oncologist in the use of both of these new therapies and the more traditional local treatments.
- Subjects
MELANOMA treatment; CANCER treatment; PROTEIN kinase inhibitors; BRAIN tumors; CANCER chemotherapy; IMMUNOTHERAPY; INTERLEUKINS; MELANOMA; MENINGEAL cancer; METASTASIS; GENETIC mutation; RADIATION; RADIOSURGERY; T cells; PROTEIN-tyrosine kinase inhibitors; DISEASE complications; THERAPEUTICS
- Publication
Oncology (08909091), 2017, Vol 31, Issue 9, p659
- ISSN
0890-9091
- Publication type
Article